Form 4: Corcept Therapeutics CFO Trades Shares

Corcept Therapeutics Chief Financial Officer, Atabak Mokari, reported a series of stock transactions on June 15, 2026, including the acquisition of stock options and the sale of common stock.

Summary

• Atabak Mokari, Chief Financial Officer of Corcept Therapeutics, engaged in stock transactions on June 15, 2026.
• Mokari acquired 40,000 stock options at an exercise price of $19.26, with an expiration date of February 2, 2032.
• He also sold a total of 30,566 shares of common stock in multiple tranches at weighted average prices ranging from $80.0216 to $82.45.
• Following these transactions, Mokari beneficially owns 46,696 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions were executed under a pre-arranged 10b5-1 plan, mitigating concerns of opportunistic trading, though the sale of shares by a key executive warrants observation.

Positives

• Acquisition of 40,000 stock options at a favorable exercise price of $19.26, indicating potential future upside.
• The CFO's continued direct beneficial ownership of 46,696 shares suggests ongoing commitment to the company.

Negatives

• Sale of 30,566 shares of common stock, potentially indicating a reduction in the CFO's direct holdings.
• The sales occurred at prices significantly higher than the exercise price of the newly acquired options.

Risks

• The sale of a substantial number of shares by a key executive could be interpreted negatively by the market, although it was conducted under a 10b5-1 plan.
• The weighted average sale prices for the shares sold ranged from $79.40 to $82.18, information on exact sale prices at each interval is available upon request from the issuer.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025.
• Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common for executives managing their personal portfolios. However, the scale of sales by a CFO can still draw market attention, even when pre-planned.

Stakeholder Impact

• Shareholders may observe the CFO's stock sales, though the 10b5-1 plan provides a degree of reassurance against negative interpretations.
• Employees may view the CFO's stock option acquisition as a positive sign of confidence in the company's future.

Next Steps

• The acquired stock options are fully exercisable.
• Information on exact sale prices can be obtained from the Issuer upon request.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, Atabak Mokari, SEC Filing